羟嗪市场，按剂型、给药途径、适应症、配销通路- 全球预测

由于焦虑症、过敏和相关疾病的盛行率不断增加，羟嗪市场规模预计在 2024 年至 2032 年期间复合年增长率为 5.4%。根据美国人口普查局家庭脉搏调查，到2023 年，大约三分之一的成年人(32.3%) 出现焦虑和忧郁症状。组织胺治疗让路。这导致作为综合治疗计划一部分的羟嗪处方比例更高。

药物配方和给药方法的技术进步也将影响市场的成长。增强的药物传递系统，例如缓释製剂，正在改善患者的依从性和治疗结果，进一步鼓励更广泛的采用。羟嗪有多种形式，包括片剂、胶囊和悬浮液，有助于满足不同患者的需求和偏好。旨在发现新治疗用途的持续研发活动也将推动产品需求。

羟嗪产业分为剂型、给药途径、适应症、配销通路和地区。

根据剂型，胶囊细分市场的市场规模预计在2024 年至2032 年期间将出现显着的复合年增长率，因为其具有易于给药、更好的患者依从性和更高的生物利用度的优势。胶囊通常受到患者和医疗保健提供者的青睐，因为与片剂相比，胶囊更容易吞嚥，特别是对于那些吞嚥困难或感到噁心的人。

由于寻求药物的患者更加容易获得和方便，预计到 2032 年，在线药房配销通路领域的羟嗪市场将录得可观的增长率。製药业电子商务的兴起使患者可以在舒适的家中轻鬆购买羟嗪，同时消除了亲自前往传统实体药局的需求。线上药局还提供有竞争力的价格和折扣，使羟嗪更实惠，对更广泛的受众更具吸引力。

由于快速城市化和生活方式的改变，过敏性疾病和精神健康障碍的盛行率不断增加，亚太地区羟嗪产业预计在 2024 年至 2032 年期间实现利润丰厚的成长。人们对心理健康问题的认识不断提高，以及与寻求治疗相关的社会耻辱感的减少，导致焦虑症的诊断和治疗率提高，从而提高了区域产品的渗透率。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 目标族群过敏反应增加
    • 增加研发投入
    • 药物输送系统的技术进步
    • 将应用扩展到过敏反应之外
  • 产业陷阱与挑战
    • 与药物相关的副作用
    • 严格的监管场景
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按剂型，2021 - 2032

• 主要趋势
• 平板电脑
• 胶囊
• 注射
• 糖浆

第 6 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 肌肉注射

第 7 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 组胺介导的搔痒
• 荨麻疹
• 异位性接触性皮肤炎

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Alliance Pharma Plc
• Amneal Pharmaceuticals, Inc.
• Aurobindo Pharma Limited
• Glenmark Pharmaceuticals Ltd.
• MYLAN N.V.
• Novartis AG
• Pfizer Inc.
• Piramal Enterprises Limited
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Limited

Hydroxyzine market size is expected to register 5.4% CAGR between 2024 and 2032 driven by the increasing prevalence of anxiety disorders, allergies, and related conditions. According to the U.S. Census Bureau Household Pulse Survey, approximately one-third of adults (32.3%) experienced symptoms of anxiety and depression in 2023. The expanding geriatric population, which is more susceptible to chronic health issues is making way for antihistamine treatment. This has led to the higher rate of prescriptions for hydroxyzine as part of comprehensive treatment plans.

Technological advancements in pharmaceutical formulations and delivery methods will also influence the market growth. Enhanced drug delivery systems, such as sustained-release formulations are improving patient compliance and therapeutic outcomes, further encouraging wider adoption. The availability of hydroxyzine in various forms, including tablets, capsules, and suspensions is helping to cater to diverse patient needs and preferences. The ongoing R&D activities aimed at discovering new therapeutic uses will also propel the product demand.

Hydroxyzine industry is segmented into dosage form, route of administration, indication, distribution channel, and region.

Based on dosage form, the market size from the capsules segment is slated to witness significant CAGR during 2024-2032 due to its advantages of ease of administration, better patient compliance, and improved bioavailability. Capsules are often preferred by patients and healthcare providers as they are easier to swallow compared to tablets, particularly for those with difficulty swallowing or experiencing nausea.

Hydroxyzine market from the online pharmacies distribution channel segment is predicted to record decent growth rate through 2032, owing to the greater accessibility and convenience to patients seeking medications. The rise of e-commerce in the pharmaceutical sector allows patients to purchase hydroxyzine easily from the comfort of their homes while eliminating the need for physical visits to traditional brick-and-mortar pharmacies. Online pharmacies also offer competitive pricing and discounts, making hydroxyzine more affordable and attractive to a broader audience.

Asia Pacific hydroxyzine industry is poised to depict lucrative growth during 2024-2032, attributed to the increasing prevalence of allergic conditions and mental health disorders due to rapid urbanization and lifestyle changes. The growing awareness about mental health issues and the reduction of social stigma associated with seeking treatment have led to the higher diagnosis and treatment rate for anxiety disorders, subsequently adding to the regional product penetration.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing allergic reaction among the target population
    • 3.2.1.2 Increasing research and development investments
    • 3.2.1.3 Technological advancements in drug delivery systems
    • 3.2.1.4 Expanding applications beyond allergic reactions
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with the medication
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Tablets
• 5.3 Capsules
• 5.4 Injections
• 5.5 Syrups

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Intramuscular

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Histamine-mediated pruritus
• 7.3 Urticaria
• 7.4 Atopic contact dermatitis

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alliance Pharma Plc
• 10.2 Amneal Pharmaceuticals, Inc.
• 10.3 Aurobindo Pharma Limited
• 10.4 Glenmark Pharmaceuticals Ltd.
• 10.5 MYLAN N.V.
• 10.6 Novartis AG
• 10.7 Pfizer Inc.
• 10.8 Piramal Enterprises Limited
• 10.9 Sun Pharmaceutical Industries Limited
• 10.10 Teva Pharmaceutical Industries Limited